Pieter van Hagen
MD, PhD
Associate Professor of Surgery
👥Biography 个人简介
Pieter van Hagen was a key investigator on the CROSS trial that established neoadjuvant chemoradiation with carboplatin-paclitaxel before esophagectomy as a global standard. The CROSS regimen remains the most widely used neoadjuvant protocol for esophageal cancer worldwide. This milestone trial demonstrated significant survival improvement with manageable toxicity.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Pieter van Hagen 的研究动态
Follow Pieter van Hagen's research updates
留下邮箱，当我们发布与 Pieter van Hagen（Erasmus MC）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment